Introduction
Hepatocyte growth factor (HGF)/scatter factor and its tyrosine kinase receptor, MET, are overexpressed across a variety of human malignancies and have been shown to promote the proliferation, migration and survival of tumor cells (1, 2) . Increased MET gene amplification and expression are associated with advanced disease and poor prognosis (3) (4) (5) (6) (7) . The HGF/MET inhibitors rilotumumab and onartuzumab showed potential antitumor activity in gastric/gastroesophageal junction (GEJ) adenocarcinomas in early clinical studies (8, 9) .
In the current Japanese guidelines, tegafur/gimeracil/oteracil (S-1) plus cisplatin is the standard of care for first-line treatment for human epidermal growth factor receptor 2-negative gastric cancer (10) . Other recommended first-line treatment options include S-1 plus oxaliplatin, S-1 plus docetaxel and capecitabine plus oxaliplatin. Cisplatin plus capecitabine (CX), an international standard firstline therapy, may also be selected and combined with targeted agents based on global Phase 3 studies (10) (11) (12) (13) (14) .
Rilotumumab (AMG 102) is a fully human monoclonal antibody (immunoglobulin G2a) that selectively binds to HGF and inhibits binding to MET, thereby suppressing HGF/MET-driven signaling pathways (8, 15) . In the initial findings available at the time this study was designed, treatment with rilotumumab plus chemotherapy (epirubicin, cisplatin, and capecitabine [ECX] ) in a global Phase 2 study of patients with advanced gastric or GEJ cancer showed trends toward improved overall survival and progression-free survival compared with chemotherapy alone (8) ; high tumor MET expression and high rilotumumab exposure were associated with better outcomes (16) .
This two-part Phase 1/1b study evaluated the safety, tolerability, and pharmacokinetics of rilotumumab in Japanese patients. In Part 1, patients with unresectable, locally advanced or metastatic carcinoma were treated with rilotumumab as monotherapy. In Part 2, patients with MET-positive, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma were treated with rilotumumab in combination with CX.
Methods

Study design and patients
The study schema is shown in Supplementary Fig. S1 . Eligible patients were Japanese men and women ≥20 years of age with an Eastern Cooperative Oncology Group performance status of 0 or 1; evaluable (measurable or nonmeasurable) disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; and adequate hematologic and organ function. Patients were excluded if they had central nervous system metastases; Grade >1 peripheral edema or peripheral neuropathy; and arterial thrombosis, vascular ischemic events, or venous thromboembolic events within 6 months before enrollment.
The study was conducted in accordance with Ministerial Ordinance on Good Clinical Practice for Drugs (Ministry of Health and Welfare Ordinance No. 28, 27 March 1997) and International Conference on Harmonisation Good Clinical Practice regulations/ guidelines. All patients provided written informed consent.
Patients eligible for Part 1 had pathologically confirmed, unresectable, locally advanced or metastatic carcinoma that was refractory to standard therapies or for which there was no standard therapy. Part 1 was a dose-escalation study that started with a cohort of three patients who received rilotumumab 10 mg/kg intravenously (IV) every 2 weeks (Q2W). If no dose-limiting toxicities (DLTs) occurred, a second cohort of six patients was to receive rilotumumab 20 mg/kg IV Q2W. If one DLT occurred, three additional patients were to be added to the first cohort. If no additional DLTs occurred in the six patients, then the second cohort was to open. If two DLTs occurred, an additional three patients were to be added to the first cohort for a total of nine patients. Only in the absence of additional DLTs in the nine patients was the second cohort to open. If three or more DLTs occurred at any time, enrollment was to be stopped and the study was to be completed. Doses in this study were based on the first-inhuman study in which the highest doses tested were 10 and 20 mg/kg Q2W and the maximum tolerated dose was not reached (17) .
Patients eligible for Part 2 had pathologically confirmed, METpositive (25% membrane positive staining in tumor assessed using the MET4 monoclonal antibody and an automated MET immunohistochemistry assay [Dako North America, an Agilent Technology Company, Carpinteria, CA, USA]), unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma; available archived tumor tissue; and the ability to tolerate infusions and take oral medications. Patients were excluded if they had received previous systemic therapy (chemotherapy, biologic, immunotherapy or investigational therapy) for gastric or GEJ adenocarcinoma. Part 2 was to be initiated if rilotumumab monotherapy was shown to be tolerable in Part 1. In Part 2, rilotumumab 15 mg/kg was given once every 3 weeks (Q3W) in combination with CX chemotherapy. The dose was based on a Phase 1b study in gastric cancer in which 15 mg/kg Q3W was evaluated in combination with ECX chemotherapy (8) . An initial cohort of six patients was evaluated for DLTs at the 15-mg/kg Q3W dose. If one or fewer DLT was observed, then the regimen was considered to be tolerable. If two DLTs occurred in the six patients, an additional three patients were to be added to the cohort. If two or fewer DLTs occurred in the nine patients, the regimen was considered to be tolerable. An additional six patients were to be evaluated at the tolerable dose.
Endpoints
The primary endpoints were adverse events and clinical laboratory abnormalities deemed to be DLTs, defined as Grade ≥3 hematologic or nonhematologic adverse events related to rilotumumab or the combination of rilotumumab and CX. DLTs did not include fatigue (except Grade 3 for >7 days or Grade 4); nausea, vomiting, or diarrhea (except Grade 3 or 4 despite maximum supportive care); neutropenia (except Grade 3 or 4 with fever >38.5°C or infection, or Grade 4 for >7 days); thrombocytopenia (except Grade 4, or Grade 3 with Grade >1 bleeding); anemia; lymphopenia; alopecia; increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST; except ALT or AST >8 × upper limit of normal [ULN], or >5 × ULN for >2 weeks for patients with baseline levels ≤2.5 ULN, or >2 × ULN for >2 weeks for patients with baseline levels >2.5-≤4 × ULN, or >3 × ULN and total bilirubin >2 × ULN or international normalized ratio >1.5 ULN); and pulmonary embolism (except those that require anticoagulation therapy). 
MET screening
To select patients for Part 2, formalin-fixed, paraffin-embedded archival tumor tissues were assessed for MET protein expression by an automated MET immunohistochemistry assay, using the MET4 monoclonal antibody (Dako North America, Inc., Carpinteria, CA, USA) (18) . A minimum of 100 tumor cells were evaluated for MET staining in the membrane. The percentage of tumor cells with no staining (0), weak staining intensity (1+), moderate staining intensity (2+), and strong staining intensity (3+) were scored and added to derive the percentage of overall MET-positive tumor cells. Samples with ≥25% of cells with MET staining intensity of 1 + or greater were considered MET positive, whereas those with <25% MET-positive cells were considered MET negative.
Statistical analysis SAS ® version 9.2 (SAS Institute Inc., Cary, NC, USA) was used to analyze this data set. Descriptive statistics were provided for demographic, safety, pharmacokinetic and efficacy parameters. Pharmacokinetic assessments were performed using noncompartmental analysis and were summarized descriptively. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 17.0 (19) and graded according to the Common Terminology Criteria for Adverse Events version 4.0 (20) . Tumor response was evaluated in the set of patients with measurable disease at baseline per RECIST version 1.1. The number and percentage of patients with a best response of complete response, partial response, stable disease or progressive disease, or who were unevaluable, or whose response assessments were not done or missing are presented for each cohort. The two-sided 95% CIs on objective response rate were constructed using the Collett exact method (21) . Duration of response was based on the investigators' assessment of response in the subset of patients who had a complete or partial response.
Results
Patients and disposition
This study was conducted between November 2012 (first patient enrolled in Part 1) and March 2015 (last patient completed followup in Part 2). Nine patients were enrolled in Part 1 (three patients received rilotumumab 10 mg/kg IV Q2W and six patients received 20 mg/kg IV Q2W), and 12 patients were enrolled in Part 2 (six patients in the initial cohort and six patients in the expansion cohort, all at rilotumumab 15 mg/kg IV Q3W plus CX). All patients were Japanese. In Part 1, the median (range) age was 59 (52-71) years, eight of nine patients (89%) had Stage IV disease, and the mean (SD) time since diagnosis was 51 (39) months (Table 1) . In Part 2, the median (range) age was 63 (44-77) years, all patients had gastric cancer, 9 of 12 patients (75%) had metastatic disease, and the mean (SD) time since diagnosis was 4 (7) months. All nine patients in Part 1 started the first cycle of rilotumumab and six patients started the second cycle; all discontinued rilotumumab due to disease progression. In Part 2, all 12 patients started the first cycle of rilotumumab plus CX, and 11, 9, and 7 patients started Cycles 2, 3 and 4, respectively. All 12 patients in Part 2 discontinued rilotumumab: seven due to disease progression, two due to patient request to discontinue treatment, one due to an adverse event, one due to sponsor decision (unrelated to the discontinuation of the rilotumumab program), and one due to withdrawal of consent from the study. Across all cohorts, the median (range) number of rilotumumab infusions per patient was 3.0 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , the median (range) cumulative weight-adjusted dose of rilotumumab to which patients were exposed was 60.0 (10-311) mg/kg, the median (range) number of days patients were on rilotumumab was 43 (1-457), and the median (range) number of days patients were on study was 169 (31-611).
Safety
No DLTs occurred in Part 1, and one patient experienced concurrent DLTs of Grade 3 decreased appetite and Grade 3 stomatitis in Part 2. Adverse events considered related to any treatment (i.e., rilotumumab, cisplatin, or capecitabine) occurred in 17/21 patients (81%); nine patients (43%) had Grade ≥3 events. The most frequently reported all-grade treatment-related adverse events were decreased appetite, nausea, fatigue and palmar-plantar erythrodysesthesia syndrome ( Table 2 ). The most frequently reported treatment-related Grade ≥3 events were decreased neutrophil count, diarrhea and palmar-plantar erythrodysesthesia syndrome. One patient had Grade 4 decreased neutrophil count, which was considered related to treatment. Three patients (14%) had serious treatment-related events: decreased appetite, deep vein thrombosis, and diarrhea. One patient (5%) who received 15 mg/kg Q3W rilotumumab in combination with CX experienced arterial thrombosis that led to discontinuation of rilotumumab.
Pharmacokinetics
Rilotumumab
In Part 1, mean exposures (C max and AUC) of rilotumumab roughly doubled as the dose doubled from 10 to 20 mg/kg Q2W and mean clearance remained similar, suggesting that the pharmacokinetics of rilotumumab are linear at this dose range in this patient population (Table 3) . In Part 2, following rilotumumab administration at 15 mg/kg Q3W in the initial cohort, the mean end-of-infusion concentrations (1 h postdose) of rilotumumab were 195, 247, 250 and 267 μg/ml in Cycles 1, 2, 3 and 4, respectively. The mean C trough levels (predose) of rilotumumab were 43.8, 71.4 and 72.7 μg/ml in Cycles 2, 3 and 4, respectively, suggesting that rilotumumab exposure reached steady state after Cycle 3.
Cisplatin and capecitabine
Following the first administration of CX, the mean (SD) C max values for total and unbound platinum were 3.84 (0.44) and 1.37 (0.08) μg/ml, respectively. The values for AUC from 0 to 23 h were 46.7 (6.6) h μg/ml for total platinum and 4.34 (0.59) h μg/ml for unbound platinum. The t ½,z was 12.3 (1.69) hours for unbound platinum. The values for C max and AUC from 0 to 5 h were 6.13 (5.22) μg/ml and 5.73 (3.94) h μg/ml for capecitabine and 0.29 (0.14) μg/ml and 0.31 (0.09) h μg/ml for 5-fluorouracil (5-FU), respectively. The t ½,z for capecitabine and 5-FU was 0.48 (0.24) and 0.65 (0.17) hours (Table 4) . Total and unbound platinum, capecitabine, and 5-FU exposure appeared to be similar across cycles, and no significant accumulation was observed.
Anti-rilotumumab antibodies
No patient developed antibodies to rilotumumab during the study. One patient tested positive for binding but not neutralizing antibodies before rilotumumab dosing.
Efficacy
Eight of the nine patients who received rilotumumab monotherapy in Part 1 had measurable disease at baseline, and all eight were evaluated as having progressive disease as best overall response ( Table 5 ). Eight of the 12 patients who received rilotumumab plus CX in Part 2 had measurable disease at baseline. Of these, five had an objective response, two had stable disease, and one had progressive disease (Table 5 ). The objective response rate (95% CI) was 0% (0-37%) in Part 1 and 63% (24-91%) in Part 2. Patient response, duration of response, and percentage of MET-positive cells at baseline for patients with measurable disease and known MET status are listed in Table 6 . At the time of the final analysis, the sum of longest diameters of target lesions ranged from 10.00 to 320.00 mm, and the maximum percentage change in tumor measurement from baseline ranged from −64% to 61% (Fig. 1) . In Part 2, median (95% CI) progression-free survival was 7.0 (2.4-15.4) months and overall survival was 18.2 (5.6-20.4) months.
Discussion
In this Phase 1 study in Japanese patients with gastric or GEJ cancer, rilotumumab as monotherapy or in combination with CX was tolerated, with linear pharmacokinetics in the dose range tested and a 63% objective response rate in patients who were MET-positive. Although these findings were initially encouraging, subsequent Phase 3 studies of both rilotumumab and onartuzumab in patients with MET-positive gastric/GEJ adenocarcinomas did not demonstrate improved clinical outcomes, and rilotumumab treatment was associated with increased mortality, which led to discontinuation of these studies (22, 23) . Given the results of those large studies targeting the MET pathway, further development of rilotumumab is not being pursued for patients with MET-positive gastric/GEJ adenocarcinoma or for the Japanese patient population. Other MET inhibitors are under investigation in the oncology setting as reviewed by Marano et al. and Zhang et al. (24, 25) ; our data may be of relevance to these efforts. There were no noteworthy differences in the exposure of rilotumumab in this Japanese patient population compared with a Western patient population using the same doses of rilotumumab monotherapy (10 and 20 mg/kg Q2W), and pharmacokinetics were linear in the dose range tested (17) . The pharmacokinetics of rilotumumab were similar in Japanese patients compared with patients in other geographic regions, and exposure was unaffected by CX, which is similar to findings in non-Japanese patients (8, 16, (26) (27) (28) .
Only one patient experienced DLTs in this study: Grade 3 decreased appetite and stomatitis. The same patient who experienced the DLTs also had a Grade 4 treatment-related adverse event of neutropenia. Gastrointestinal and hematologic adverse events as well as palmar-plantar erythrodysesthesia syndrome were the most common types of adverse events in this study and are known toxicities of CX chemotherapy (12, 14, 29, 30) . Hematologic toxicities have been reported to be higher in frequency with rilotumumab plus chemotherapy than with chemotherapy alone (8) . Other adverse events previously associated with rilotumumab, including peripheral edema and deep vein thrombosis (8) , were also reported in this study. The adverse events reported for onartuzumab, which include edema, hypoalbuminemia, gastrointestinal perforation, venous thromboembolism, and arterial thromboembolism (31) , are generally similar to those reported here and may be related to the common mechanism of action of these MET inhibitors.
Although none of the patients with locally advanced or metastatic carcinoma in Part 1 responded to rilotumumab monotherapy, analysis of archival tumor tissue determined that five of these patients (including one patient with gastric cancer) were MET positive. Five of the eight patients with measurable disease and MET-positive locally advanced or metastatic gastric or GEJ adenocarcinoma in Part 2 had a partial response to rilotumumab in combination with CX. The percentage of MET-positive cells in the five responders ranged from 40% to 95%; similarly, the percentage of MET-positive cells in the three nonresponders ranged from 35% to 95%. Because of the small sample size, MET amplification was not analyzed. Correlations between MET expression, intensity of expression, and tumor response were investigated, but results were inconclusive owing to small sample size. Tumor volume decreased in response to rilotumumab by as much as 64%.
The limitations of this study are the small sample size, descriptive analyses and premature study termination, permitting hypothesis generation rather than definitive conclusions.
In conclusion, rilotumumab alone and in combination with chemotherapy was tolerated in Japanese patients with gastric or GEJ cancers, and there were no notable differences in pharmacokinetics compared with patients from other geographic regions. Five patients treated with rilotumumab in combination with CX had a best response of partial response. Despite the acceptable tolerability and pharmacokinetic findings in this study, further exploration of rilotumumab is not warranted given the results of a Phase 3 trial of rilotumumab in gastric/GEJ cancer reported elsewhere (22) . Postdose a (n = 12) Predose (n = 11) Postdose a (n = 11) Predose (n = 9) Postdose a (n = 9) Predose (n = 7) Postdose a (n = 7)
15 mg/kg Q3W 195 (41) 44 (20) 247 (65) 71 (27) 250 ( CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. a Required on-study imaging of stable disease or better ≥7 weeks after cycle 1 day 1 for Part 1 and ≥5 weeks after cycle 1 day 1 for Part 2.
